Ardea Biosciences have announced it will present data on its MEK inhibitor, RDEA119, at the American College of Gastroenterology Annual Scientific Meeting at the Gaylord Palms Resort & Convention Center in Orlando.
Filed under: kinase | Tagged: Ardea, Ardea Biosciences, ERK, MEK, RDEA-119, RDEA119 | Comments Off
Five Prime have initiated a Phase I trial of its FGFR1:Fc fusion protein FP-1039, in patients with advanced solid tumors.
Filed under: Kinase receptor | Tagged: FGFR1, Five Prime, FP-1039, FP1039, Kinase receptor, phase I | Comments Off
Boehringer Ingelheim have published3 papers on Inducible T-Cell Kinase (Itk):
- A series of 5-Aminomethyl-1H-benzimidazoles
- A series of 1H-Benzoimidazole-5-carboxylic acid cyclohexyl-methyl-amides
- Lead optimization of a Benzimidazole Lead compound
Filed under: kinase | Tagged: boehringer-ingelheim, Inducible T-Cell Kinase, itk, kinase, Preclinical, Research | Comments Off
Novartis have announced that RAD001 (everolimus) has been granted priority review by the US FDA for the treatment of patients with advanced kidney cancer after failure of standard treatment. Marketing authorization applications for RAD001 have also been filed with the EMEA and Swissmedic. The proposed brand name for RAD001 is Afinitor
Filed under: kinase | Tagged: Afinitor, everolimus, kinase, mTOR, Novartis, RAD-001, RAD001, regulatory | Comments Off
